Lv1
40 积分 2025-04-12 加入
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in China
17天前
已完结
Simplified perioperative serplulimab and chemotherapy for resectable squamous NSCLC: a phase II trial with biomarker analysis
19天前
已完结
Neoadjuvant nonablative stereotactic body radiotherapy plus immunotherapy yields similar pathologic response as chemoimmunotherapy in non–small cell lung cancer
20天前
已完结
Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial
20天前
已完结
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer
20天前
已完结
Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis
21天前
已完结
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration
1个月前
已完结
First-line integration of Local Ablative Therapy (LAT) with EGFR Tyrosine Kinase Inhibitors (TKIs) in advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis
1个月前
已关闭
Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study
1个月前
已完结
Perioperative Outcomes of Robotic- vs Video-Assisted Thoracoscopic Surgery in Non-Small Cell Lung Cancer After Neoadjuvant Therapy
2个月前
已关闭
皖公网安备34019202002308
